Nuvectis Pharma, Inc.
NVCT
$9.05
$0.627.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.89M | 1.95M | 1.54M | 1.70M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.57M | 6.45M | 4.36M | 4.64M | 4.40M |
| Operating Income | -5.57M | -6.45M | -4.36M | -4.64M | -4.40M |
| Income Before Tax | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M |
| EBIT | -5.57M | -6.45M | -4.36M | -4.64M | -4.40M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.27 | -0.35 | -0.24 | -0.26 | -0.25 |
| Normalized Basic EPS | -0.17 | -0.22 | -0.15 | -0.16 | -0.16 |
| EPS Diluted | -0.27 | -0.35 | -0.24 | -0.26 | -0.25 |
| Normalized Diluted EPS | -0.17 | -0.22 | -0.15 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 19.94M | 17.76M | 17.23M | 16.90M | 16.56M |
| Average Diluted Shares Outstanding | 19.94M | 17.76M | 17.23M | 16.90M | 16.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |